3.36MMarket Cap-0.18P/E (TTM)
2.7500High2.6200Low12.08KVolume2.7200Open2.6700Pre Close32.29KTurnover1.33%Turnover RatioLossP/E (Static)1.27MShares9.400052wk High0.19P/B2.41MFloat Cap2.600052wk Low--Dividend TTM908.92KShs Float170.0000Historical High--Div YieldTTM4.87%Amplitude2.6000Historical Low2.6730Avg Price1Lot Size
Pasithea Therapeutics Stock Forum
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
54 seconds ago, 4:02 AM PST
Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule --
-- No dose-limiting toxicities (DLTs) observed to date --
-- No rash observed to date --
📊⚡️📊
Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules
No comment yet